ERBB2 and neoplasm: [18F]FES targeting the ER, [64Cu]- or [89Zr]Trastuzumab targeting HER2, or [18F]FTT targeting PARP enable personalized medicine approaches by tailoring treatment strategies to the individual characteristics of the tumor.